Skip to content
MarketDeck StockProof
NATCOPHARM.NS

NATCO Pharma Ltd.

Healthcare
Price research

Price history

3Y window · 2023-09-25 to 2026-09-23

Start 2023-09-25 ₹848.50
End 2026-09-23 ₹837.60
Change over window -1.28%
Methodology

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical analysis

Technical indicators

Same window as the price chart above

These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

Latest value of each line in the charted window
Methodology

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Ratios as of FY2025-26 Annual filing · published 2026-05-29
Price (live) ₹815.05 INR fetched 2026-09-23 02:28
Fundamental analysis

Ratios

Calculated from this company's filed figures, and from the current price where a ratio needs one. Every ratio shows its source trace: the filed elements it reads and the arithmetic behind the result.

P/E

10.29

P/E = Price / EPS

Source trace FY2025-26 · Annual filing

P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹815.05 / (₹14,185,000,000 / 179,000,000 shares) = ₹815.05 / ₹79.25 EPS

ROE

15.38%

ROE = Net Income / Shareholder Equity

Source trace FY2025-26 · Annual filing

ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹14,185,000,000 / ₹92,211,000,000 = 15.38%

Debt/Equity

0.08

Debt/Equity = Total Debt / Shareholder Equity

Source trace FY2025-26 · Annual filing

Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹7,064,000,000 / ₹92,211,000,000 = 0.08

Current Ratio

3.01

Current Ratio = Current Assets / Current Liabilities

Source trace FY2025-26 · Annual filing

Current Ratio = CurrentAssets / CurrentLiabilities → ₹50,523,000,000 / ₹16,809,000,000 = 3.01

ROCE

15.39%

ROCE = EBIT / (Shareholder Equity + Total Debt)

Source trace FY2025-26 · Annual filing

ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹15,275,000,000 / (₹92,211,000,000 + ₹7,064,000,000) = 15.39%

Dividend Yield

0.62%

Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

Qualification This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace FY2025-26 · Annual filing

Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹902,000,000 / 179,000,000 shares) / ₹815.05 = ₹5.04 / ₹815.05

Growth & quality

Growth & earnings trend

Computed from this company's stored annual filings. Each figure carries the filed values behind it as a tooltip.

Revenue CAGR · 3y 14.7%
Net profit CAGR · 3y 26.3%
Operating margin · FY2025-26 37.5%
ROCE · FY2025-26 15.4%

Revenue & Profit CAGR

Revenue (3y, 5.0y actual)
14.7%
Net Profit (3y)
26.3%
Revenue (5y, 5.0y actual)
14.7%
Net Profit (5y)
26.3%
Revenue (10y, 5.0y actual)
14.7%
Net Profit (10y)
26.3%

Operating Margin Trend

Expanding
FY2020-21
28.9%
FY2021-22
11.3%
FY2022-23
32.4%
FY2023-24
42.3%
FY2024-25
52.3%
FY2025-26
37.5%

ROCE Trajectory

FY2020-21
N/A
FY2021-22
N/A
FY2022-23
17.4%
FY2023-24
27.2%
FY2024-25
29.4%
FY2025-26
15.4%

Earnings Quality

No persistent gap detected

Net Profit CAGR 69.96% vs CFO CAGR 148.33% over 4.0y (2022-03-31 → 2026-03-31); most recent year: Net Profit -24.76% vs CFO +4.21%

Sector-Relative Percentile

Sector · Healthcare
ROE 57th percentile Better than 26 of 46 sector peers (57th percentile).
ROCE 43th percentile Better than 20 of 46 sector peers (43th percentile).
Debt/Equity 57th percentile Better than 26 of 46 sector peers (57th percentile).
P/E 96th percentile Better than 44 of 46 sector peers (96th percentile).
Forensic accounting

Beneish M-Score

Eight year-over-year accounting indices (Beneish, 1999) computed for NATCO Pharma Ltd. across its two most recently stored annual filings. Read the disclosures below before anything past this paragraph.

This is not an accusation and not a finding that any manipulation occurred. Beneish's own paper is explicit that the score identifies companies whose accounting CHARACTERISTICS resemble those of a sample of past manipulators -- nothing more. StockProof never labels a company "manipulator", "red flag" or "suspicious", and never shows any list of companies ordered by this score. The eight components below -- factual statements about figures the company itself filed -- always come before the composite number, which is the inference, not the fact.

The M-Score is calibrated on 74 US-listed companies from 1982-1992 later found to have manipulated earnings (Beneish, M. D. (1999), "The Detection of Earnings Manipulation", Financial Analysts Journal 55(5)) -- not on any Indian company or era. Measured on StockProof's own Nifty 500 universe as of 2026-09-02, 13.6% of companies score above Beneish's own published cutoff. On any realistic base rate of actual earnings manipulation, that flag rate is overwhelmingly false positives, not overwhelmingly real ones.

No "Selling, General & Administrative Expense" element exists anywhere in NSE's filed data. The SGAI component below is approximated as Employee Benefit Expense + Other Expenses, divided by revenue -- a reasonable stand-in for a manufacturer, but for a services company this proxy is closer to the entire cost base than to SG&A specifically. This is disclosed because it is a genuine deviation from Beneish's published specification; its coefficient (-0.172) is the smallest of the eight, which bounds how far the approximation can move the composite.

This measures something different from a financial-distress score like Altman's Z-Score, and the two essentially never agree. Measured on StockProof's own 389-company overlap as of 2026-09-02: only 5 companies were flagged by both, an agreement rate (intersection ÷ union) of 6.2%, and a correlation between the two scores of +0.088 -- closely matching the independently measured +0.092 over 3,242 Malaysian-listed companies. A low Z-Score and a high M-Score are not corroborating each other; they are unrelated measurements.

Comparing FY2024-25FY2025-26

Index Value Beneish's own threshold Reading, vs. that threshold
DSRI — Days' Sales in Receivables Index 0.768 1.031 Below Beneish's published threshold
GMI — Gross Margin Index 1.016 1.014 Exceeds Beneish's published threshold
AQI — Asset Quality Index 2.917 1.039 Exceeds Beneish's published threshold
SGI — Sales Growth Index 0.921 1.134 Below Beneish's published threshold
DEPI — Depreciation Index 1.175 1.077 Exceeds Beneish's published threshold
SGAI — SG&A Index 1.373 1.041 Exceeds Beneish's published threshold
LVGI — Leverage Index 1.471 1.111 Exceeds Beneish's published threshold
TATA — Total Accruals to Total Assets -0.032 0.018 Below Beneish's published threshold
M-Score (composite) -2.327 Beneish's own published cutoff: -1.78 (a looser cutoff sometimes used in Indian applications: -2.22)

This is a reading against a published statistical model, not a finding and not a verdict on this company -- see the disclosures above, especially how this compares to a general population's own measured false-positive rate.

Financials

Quarterly trend

10 stored quarters

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹1,068.30 Cr. ₹1,362.60 Cr. ₹1,371.10 Cr. ₹474.80 Cr. ₹1,221.00 Cr. ₹1,328.90 Cr. ₹1,363.00 Cr. ₹647.30 Cr. ₹739.10 Cr. ₹735.20 Cr. RevenueFromOperations
Net Profit ₹386.30 Cr. ₹668.50 Cr. ₹677.30 Cr. incl. minority ₹676.50 Cr. ₹133.00 Cr. incl. minority ₹132.40 Cr. ₹406.60 Cr. incl. minority ₹406.00 Cr. ₹480.70 Cr. incl. minority ₹480.30 Cr. ₹518.40 Cr. incl. minority ₹517.90 Cr. ₹151.50 Cr. incl. minority ₹151.30 Cr. ₹267.90 Cr. incl. minority ₹269.00 Cr. ₹206.50 Cr. ProfitOrLossAttributableToOwnersOfParent
Basis

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10).

Ownership

Shareholding pattern

Latest filing Jun 2026 · 12 filings on file

Promoter & Promoter Group
49.42%
Public
50.58%
Employee Trusts
0.00%
Promoter % Public %
Metric Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter & Promoter Group 49.71% 49.71% 49.71% 49.71% 49.62% 49.62% 49.56% 49.56% 49.48% 49.48% 49.42% 49.42%
Public 50.29% 50.29% 50.29% 50.29% 50.38% 50.38% 50.44% 50.44% 50.52% 50.52% 50.58% 50.58%
Employee Trusts 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Source

Promoter vs. public shareholding, from NSE's own quarterly shareholding-pattern filings. This is the headline promoter/public split only — a further breakdown by FII/DII/mutual fund holders requires each filing's own detailed disclosure and isn't shown here.

Trading activity

Delivery volume

20 trading days shown

Latest (2026-09-23) 50.7%
Trailing 20-day average 53.6%
Date Traded Qty Delivery Qty Delivery %
2026-09-23 650820 329873 50.69%
2026-09-22 619357 341829 55.19%
2026-09-21 451347 272852 60.45%
2026-09-18 489351 297976 60.89%
2026-09-17 340518 165576 48.62%
2026-09-16 492595 250779 50.91%
2026-09-15 434634 210940 48.53%
2026-09-11 567956 254682 57.38%
2026-09-10 236487 127636 53.97%
2026-09-09 537495 206622 38.44%
2026-09-08 302502 184563 61.01%
2026-09-07 301243 156140 51.83%
2026-09-04 445370 269252 60.46%
2026-09-03 217962 114569 52.56%
2026-09-02 472795 251295 53.15%
2026-09-01 241430 130089 53.88%
2026-08-31 412911 252348 61.11%
2026-08-28 402204 230311 57.26%
2026-08-27 279220 139700 50.03%
2026-08-26 371204 172898 46.58%
Source

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero.

Insider trading activity

20 disclosures shown

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake Source
11 Mar 2026 SANJAY NANNAPANENI Promoter Group Sell Market Sale 70000 71211373 0.09% XBRL
11 Mar 2026 SATYA VANI NANNAPANENI Promoter Group Sell Market Sale 45000 45059895 0.19% XBRL
01 Oct 2025 SANJAY NANNAPANENI Promoter Group Sell Market Sale 100000 80305214 0.13% XBRL
17 Sep 2025 SATYA VANI NANNAPANENI Promoter Group Sell Market Sale 23000 19720002 0.21% XBRL
11 Sep 2025 SATYA VANI NANNAPANENI Promoter Group Sell Market Sale 17149 14519670 0.22% XBRL
12 Jun 2025 PRAGNYA RAO DONTHINENI Other Buy Market Purchase 100 86500 0.00% XBRL
27 Mar 2025 SANJAY NANNAPANENI Promoter Group Buy Off Market 286910 0 0.18% XBRL
21 Mar 2025 VENKATA SATYA SWATHI KANTAMANI Promoter Group Sell Off Market 50000 0 8.90% XBRL
21 Mar 2025 RAJEEV NANNAPANENI Promoters Sell Off Market 50000 0 0.60% XBRL
03 Mar 2025 SATYA VANI NANNAPANENI Promoter Group Buy Others 420000 0 0.23% XBRL
03 Mar 2025 SANJAY NANNAPANENI Promoter Group Buy Others 40000 0 0.02% XBRL
31 Dec 2024 TUMMALA VENKAT RAO Employees/Designated Employees Sell Market Sale 2500 3450942 0.03% XBRL
31 Dec 2024 Lakshminarayana Bolisetty Director Sell Market Sale 2000 2783220 0.00% XBRL
21 Dec 2024 SADA SIVA RAO. NANNAPANENI Employees/Designated Employees Sell Market Sale 5000 7336084 0.04% XBRL
02 Dec 2024 TUMMALA RAHUL Other Sell Market Sale 1000 1352855 0.00% XBRL
28 Nov 2024 TUMMALA RAHUL Other Sell Market Sale 900 1223319 0.00% XBRL
12 Sep 2024 AMIT SOGANI - Sell Market Sale 1500 2426355 0.00% XBRL
06 Sep 2024 SUNIL KOTARU - Sell Market Sale 1310 2039178 0.00% XBRL
05 Sep 2024 G VENKATA RAMANA - Sell Market Sale 2000 3066041 0.00% XBRL
02 Sep 2024 M SUBBA RAO - Sell Market Sale 20000 30279976 0.02% XBRL
About these disclosures

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell.

Filings & evidence

Source documents

FY2025-26 · Annual filing

The raw filing line items behind the figures on this page, and NSE's own filing document where NSE publishes one.

Source document — income statement (FY2025-26, raw filing line items)
Line itemFiled value
ProfitOrLossAttributableToOwnersOfParent14185000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital179000000.0
Source document — balance sheet (FY2025-26, raw filing line items)
Line itemFiled value
CurrentAssets50523000000.0
CurrentLiabilities16809000000.0
EquityAttributableToOwnersOfParent92211000000.0
BorrowingsCurrent + BorrowingsNoncurrent7064000000.0
Research notes

My notes